MHC-presented MYB-derived antigenic peptide

MHC-presented MYB-derived antigenic peptides are short peptide fragments originating from the MYB transcription factor (or its derivates) that are processed intracellularly and loaded onto major histocompatibility complex (MHC) molecules for display on the cell surface[1][2][3]. These complexes, consisting of a peptide bound in the MHC groove, are recognized by T cell receptors (TCRs), enabling cytotoxic or helper T cells to detect and respond to cells expressing these peptides[2][3][4][5]. MYB-derived antigenic peptides may arise from both canonical and noncanonical translation events, including alternative splicing or non-AUG-initiated translation[5]. Their immunological relevance is determined by their potential to be presented specifically by tumor or virally infected cells, or to trigger tolerance or autoimmunity in some contexts[5]. As such, they represent potential therapeutic targets in cancer immunotherapy (especially when unique to malignant cells), vaccine development, and the study of immune evasion[5][6]. Their interaction is not with a classic "receptor," but through the peptide–MHC complex engaging the TCR. Their drug target potential is indirect—targeting the peptide–MHC complex for immunotherapeutic manipulation.

Other names

MHC-peptide complex (MYB-derived)MYB antigenic peptide (MHC-presented)

Induces T cell-mediated immune response (when presented by MHC molecules and recognized by TCR) Can be targeted by adoptive cell therapies (e.g., TCR-T, CAR-T if engineered against the peptide–MHC complex)